Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Organon logo
OrganonOGN
$5M+145%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's change in fair value of contingent consideration?
Cumberland Pharmaceuticals (CPIX) reported change in fair value of contingent consideration of -$228.97K in Q1 2026.
How has Cumberland Pharmaceuticals's change in fair value of contingent consideration changed year-over-year?
Cumberland Pharmaceuticals's change in fair value of contingent consideration decreased by 609.1% year-over-year, from $44.98K to -$228.97K.
What is the long-term trend for Cumberland Pharmaceuticals's change in fair value of contingent consideration?
Over 2 years (2022 to 2024), Cumberland Pharmaceuticals's change in fair value of contingent consideration has grown at a -16.4% compound annual growth rate (CAGR), from -$2.09M to -$1.46M.
What does change in fair value of contingent consideration mean?
Represents the non-cash adjustment to the fair value of liabilities related to acquisition-based earn-outs or performance milestones. Fluctuations in this metric reflect changes in the estimated probability or timing of future payments to sellers of acquired businesses. Investors monitor this to assess the volatility of acquisition-related obligations and potential future cash outflows.